National Institutes of Health: Carcinoma, Merkel Cell trials

The registry lists 11 Carcinoma, Merkel Cell studies with National Institutes of Health as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 3Phase 2 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2
• Studies of Dermatologic Diseases Biospecimen Acquisition ProtocolRecruitingNCT02471352
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results posted
• Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell CarcinomaCompletedNCT03304639Phase 2Results posted
• Pembrolizumab in Treating Patients With Advanced Merkel Cell CancerCompletedNCT02267603Phase 2Results posted
• Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruitingNCT05947500Phase 2
• Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 2
• Study of the Drug Ipilimumab for Metastatic Merkel Cell CarcinomaWithdrawnNCT01913691Phase 2
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• Oblimersen in Treating Patients With Merkel Cell CarcinomaCompletedNCT00079131Phase 2
• S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerCompletedNCT00068783Phase 2